Top

Published in:

Open Access 07-03-2024 | Vulgar Psoriasis | Original Research

A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State

Authors: Tom M. Hillary, Tine Vanhoutvin, Miet Peeters, Maya Imbrechts, Thomas Vanassche, Marjan Garmyn, Séverine Vermeire

Published in: Dermatology and Therapy | Issue 3/2024

Abstract

Introduction

Chronic inflammatory diseases, including psoriasis, are associated with development of venous thromboembolism (VTE). The clot lysis profile (CLP) provides information on both the clotting tendency and fibrinolysis activity. We hypothesized that CLP in uncontrolled psoriasis patients is disturbed towards more clotting/less lysis compared to healthy controls (HC) and that successful psoriasis treatment could normalize the CLP. In this project, we aim to compare the CLP in patients with uncontrolled psoriasis with age- and sex-matched HC and investigate the effect of anti-inflammatory treatment on CLP.

Methods

Patients with uncontrolled psoriasis [psoriasis area severity index (PASI) or body surface area (BSA) > 10] (n = 87) and HC (n = 87) were recruited at a tertiary dermatology department. Samples from patients were obtained before treatment and when disease control was obtained (PASI < 3). Amplitude, area under the curve (AUC) and 50% clot lysis time were determined.

Results

At baseline, psoriasis patients had higher median amplitude and AUC compared with HC (p < 0.0001). After correction for possible confounders (BMI, smoking behavior, psoriatic arthritis, arterial hypertension, diabetes and coronary artery disease), the increased amplitude in psoriasis patients compared to HC remained significant. Successful anti-inflammatory treatment resulted in a significant decrease in amplitude (p = 0.0365).

Conclusion

This is the first prospective study comparing the CLP of psoriasis patients with that of HC. A significant increase in both amplitude and area under the curve, indicative of a hypercoagulable CLP, was observed in psoriasis patients compared to HC. After successful anti-inflammatory treatment, amplitude significantly decreased.

Available only for authorised users

Alshobaili HA, Shahzad M, Al-Marshood A, Khalil A, Settin A, Barrimah I. Genetic background of psoriasis. Int J Health Sci (Qassim). 2010;4(1):23–9.PubMed

Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840–8.CrossRefPubMed

Egeberg A, Mallbris L, Warren RB, et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. Br J Dermatol. 2016;175(3):487–92.CrossRefPubMed

Al-Janabi A, Yiu ZZN. Biologics in psoriasis: updated perspectives on long-term safety and risk management. Psoriasis (Auckl). 2022;12:1–14.PubMed

Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26(Suppl 2):3–11.CrossRefPubMed

Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147–51.CrossRefPubMed

Späh F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol. 2008;159(Suppl 2):10–7.CrossRefPubMed

Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–41.CrossRefPubMed

Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303–7.CrossRefPubMed

10.

Chen T-L, Lee L-L, Huang H-K, et al. Association of psoriasis with incident venous thromboembolism and peripheral vascular disease: a systematic review and meta-analysis. JAMA Dermatol. 2022;158(1):59–67.CrossRefPubMed

11.

Ahlehoff O, Gislason GH, Lindhardsen J, et al. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS ONE. 2011;6(3): e18125.CrossRefPubMedPubMedCentral

12.

Ogdie A, Kay McGill N, Shin DB, et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. Eur Heart J. 2018;39(39):3608–14.CrossRefPubMed

13.

Hillary T, Clijmans J, Vermeire S, et al. Venous thrombotic events in psoriasis patients: a systematic review with meta-analysis. Ann Med. 2021;53(1):1074–81.CrossRefPubMed

14.

Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464–74.CrossRefPubMedPubMedCentral

15.

White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I4-8.PubMed

16.

Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res. 2016;137:3–10.CrossRefPubMed

17.

Annemans L, Robays H, Bruart J, Verstraeten P. Variation in medical resource utilisation in the management of pulmonary embolism in Belgium. Acta Clin Belg. 2002;57(1):11–8.CrossRefPubMed

18.

Damian AC, Colaco K, Rohekar S, et al. The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis. Semin Arthritis Rheum. 2021;51(3):547–52.CrossRefPubMed

19.

Hillary T, Grymonprez M, Vanhooren E, Güvenç C, Garmyn M, Vermeire S. Venous thromboembolism in psoriasis patients: a retrospective monocentric chart review on an overlooked comorbidity. Clin Exp Dermatol. 2023;49:75–6.CrossRefPubMed

20.

Mackman N. New insights into the mechanisms of venous thrombosis. J Clin Invest. 2012;122(7):2331–6.CrossRefPubMedPubMedCentral

21.

Aksu K, Donmez A, Keser G. Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des. 2012;18(11):1478–93.CrossRefPubMed

22.

Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005;105(3):1102–5.CrossRefPubMed

23.

Bollen L, VandeCasteele N, Peeters M, et al. Short-term effect of infliximab is reflected in the clot lysis profile of patients with inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2015;21(3):570–8.CrossRefPubMed

24.

von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019;139(5):1054–62.CrossRef

25.

Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019;115(4):721–8.CrossRefPubMedPubMedCentral

26.

Li Y, Golden JB, Camhi MI, et al. Protection from psoriasis-related thrombosis after inhibition of IL-23 or IL-17A. J Invest Dermatol. 2018;138(2):310–5.CrossRefPubMed

27.

(FDA) USFaDA. 2021. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death#:~:text=FDA%20is%20requiring%20new%20and,%2C%20and%20Rinvoq%20(upadacitinib). Accessed 01 Dec 2023.

28.

Posch F, Hofer S, Thaler J, et al. Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death. Transl Res. 2020;215:41–56.CrossRefPubMed

29.

Traby L, Kollars M, Eischer L, Eichinger S, Kyrle PA. Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study. PLoS ONE. 2012;7(12): e51447.CrossRefPubMedPubMedCentral

Title: A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State
Authors: Tom M. Hillary
Tine Vanhoutvin
Miet Peeters
Maya Imbrechts
Thomas Vanassche
Marjan Garmyn
Séverine Vermeire
Publication date: 07-03-2024
Publisher: Springer Healthcare
Keyword: Vulgar Psoriasis
Published in: Dermatology and Therapy / Issue 3/2024
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI: https://doi.org/10.1007/s13555-024-01126-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2024

Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis’

Successful Treatment of Disseminated Granuloma Annulare with Upadacitinib

Effect of Makeup Use on Depressive Symptoms: An Open, Randomized and Controlled Trial

Insights into Early Systemic Treatment in Atopic Dermatitis: Scientific Facts and Practical Considerations

The Role of the Gut-Joint Axis in the Care of Psoriatic Arthritis: A Two-Sample Bidirectional Mendelian Randomization Study

Botulinum Toxin A and B for Palmoplantar Hyperhidrosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials